NexGard Combo
esafoxolaner / eprinomectin / praziquantel
Table of contents
Overview
NexGard Combo is an antiparasitic veterinary medicine used to treat mixed infections with external parasites (fleas, ticks or mites) and internal parasites (tapeworm and roundworms) in cats.
The medicine should only be used in confirmed mixed infections or if cats are at significant risk of mixed infection with external parasites and roundworms and need treatment against tapeworm at the same time. If there is no risk of co-infestation, a narrower spectrum antiparasitic medicine should be considered.
For external parasites, an application of NexGard Combo can treat flea and tick infestation for one month. It can also be used to treat infestations with ear or skin mites and as part of the management of flea allergy dermatitis (an allergic skin reaction to flea bites).
For internal parasites, NexGard Combo can be used to treat infections with tapeworms and roundworms/hookworms in the gut as well as lungworms and a roundworm that infects the bladder. NexGard Combo can also be used to prevent heartworm disease for one month per application.
NexGard Combo contains the active substances esafoxolaner, eprinomectin and praziquantel.
Authorisation details
Product details | |
---|---|
Name |
NexGard Combo
|
Agency product number |
EMEA/V/C/005094
|
Active substance |
|
International non-proprietary name (INN) or common name |
|
Species |
Cats
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QP54AA54
|
Publication details | |
---|---|
Marketing-authorisation holder |
Boehringer Ingelheim Vetmedica GmbH
|
Revision |
1
|
Date of issue of marketing authorisation valid throughout the European Union |
06/01/2021
|
Contact address |
55216 Ingelheim am Rhein |
Product information
29/11/2021 NexGard Combo - EMEA/V/C/005094 - II/0002/G
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
-
Eprinomectin, combinations
-
Avermectins
-
Antiparasitic products, insecticides and repellents
Therapeutic indication
For cats with, or at risk from mixed infections by cestodes, nematodes and ectoparasites. The veterinary medicinal product is exclusively indicated when all three groups are targeted at the same time.